Does SummaCare Cover Wegovy?
The verdict
Conditional on most plans
SummaCare's Wegovy coverage is employer-dependent and not publicly published in detail; weight-loss coverage exists only where the employer purchased the anti-obesity benefit, and you must verify via the plan's drug-lookup tool. Medicare Advantage covers the cardiovascular risk-reduction indication with prior authorization; weight-loss use is excluded from Medicare Part D by statute, but the Medicare GLP-1 Bridge provides weight-loss access at $50/month from July 1, 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with SummaCare using your member ID.
Key facts
Medicare Part D cannot cover Wegovy for weight loss by statute; the Medicare GLP-1 Bridge ($50/month) launches July 1, 2026 to fill that gap for eligible beneficiaries.
CMS.gov — Medicare GLP-1 Weight Loss Drug Access Program
Wegovy is FDA-approved for chronic weight management (BMI ≥30, or ≥27 with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD — distinct from Ozempic, which is approved only for type 2 diabetes.
FDA — Wegovy (semaglutide injection 2.4 mg) prescribing information
Only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026, with several states dropping coverage during 2025.
KFF — Medicaid Coverage of and Spending on GLP-1s
Medicare vs. commercial coverage
Whether SummaCare covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
SummaCare Medicare Advantage (Part D) cannot cover Wegovy for weight loss by statute. Wegovy's cardiovascular risk-reduction indication — FDA-approved for adults with established CVD who are overweight or obese — is coverable under Medicare Advantage with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible SummaCare Medicare Advantage members weight-loss access to Wegovy at a fixed $50/month copay. The Bridge operates outside Part D: the $50 copay does not count toward the $2,100 Part D OOP cap or TrOOP, and Extra Help cannot be applied to it. Bridge eligibility (provider attests at initiation): BMI ≥35; or BMI ≥30 with heart failure, uncontrolled hypertension, or CKD; or BMI ≥27 with prediabetes, prior heart attack, prior stroke, or symptomatic PAD. Members already receiving a Part D-covered GLP-1 are not eligible for the Bridge. NovoCare savings card is not available to Medicare beneficiaries. Verify your SummaCare Medicare Advantage plan's specific PA criteria on the plan's drug list.
Commercial / Employer
Group & marketplace plans
SummaCare commercial and employer plans cover Wegovy for weight loss only where the employer purchased the anti-obesity benefit. SummaCare, affiliated with Summa Health in northeastern Ohio, does not publish drug-level Wegovy formulary specifics, so coverage cannot be confirmed without checking the plan drug-lookup tool and asking HR whether anti-obesity medications are included in your benefit design. Where the employer benefit exists, prior authorization with baseline BMI and comorbidity criteria is required for approval. ACA/individual-market plans generally exclude weight-loss GLP-1s. Commercially insured members whose SummaCare plan covers Wegovy may use the NovoCare savings card to pay as little as $25/month (max $100 per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period (introductory pricing through December 31, 2026).
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where the employer anti-obesity benefit is active — not publicly published. Use the SummaCare drug-lookup tool with your member ID to confirm your tier and cost-share. Commercially insured members whose plan covers Wegovy may use the NovoCare savings card for as little as $25/month (max $100/28-day supply).
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month for eligible Medicare Advantage beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — the $50 copay does not count toward the $2,100 OOP cap or TrOOP.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates and vary by plan tier and pharmacy. Verify actual cost-share on the SummaCare member portal or by calling member services before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check the SummaCare drug-lookup tool
Visit summacare.com and use the drug-lookup or formulary search tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to see whether your specific plan includes the drug and, if so, what tier and PA requirements apply. SummaCare does not publish drug-level Wegovy specifics outside of the member portal.
- 2
Confirm with HR whether your employer's plan includes the anti-obesity benefit
Even if your SummaCare plan type generally covers weight-loss GLP-1s, the benefit is only available if your employer purchased it. Ask your HR or benefits administrator directly whether anti-obesity medications are in your plan design. A benefit exclusion cannot be resolved through a PA or medical-necessity appeal.
- 3
Work with your prescriber on prior authorization
If the employer benefit is confirmed, your prescriber will document your BMI, any qualifying comorbidities, and participation in a weight-management program. For Medicare Advantage members seeking the cardiovascular indication, confirm that established CVD is documented in your medical record. Track weight-loss progress for renewal — standard renewal criteria include at least 5% documented weight loss.
Options if SummaCare won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Medicare GLP-1 Bridge (Medicare Advantage members)
Starting July 1, 2026, eligible SummaCare Medicare Advantage members can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge program, which operates outside Part D. Eligibility requires BMI ≥35 or qualifying conditions; patients already on a Part D-covered GLP-1 are excluded.
NovoCare self-pay program
NovoCare Pharmacy offers Wegovy at approximately $349/month without insurance coverage, after an introductory period. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
SummaCare covers Wegovy for weight loss only on commercial plans where the employer purchased the anti-obesity benefit. The plan does not publish drug-level Wegovy formulary detail, so you must use the SummaCare drug-lookup tool and confirm with HR whether anti-obesity drugs are in your benefit design. Where the employer benefit exists, prior authorization is required. ACA/individual plans generally exclude weight-loss GLP-1s. Your coverage status cannot be confirmed without checking your specific plan.
SummaCare Medicare Advantage cannot cover Wegovy for weight loss under Medicare Part D by statute. It can cover Wegovy for the cardiovascular risk-reduction indication (for adults with established CVD who are overweight or obese) with prior authorization. Starting July 1, 2026, eligible Medicare Advantage members can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge, which operates outside Part D and does not count toward the $2,100 OOP cap. Verify PA criteria on the SummaCare plan drug list.
The Medicare GLP-1 Bridge is a federal program running July 1, 2026 through December 31, 2027 that gives eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month, outside the Part D benefit. Eligible SummaCare Medicare Advantage members can participate if they meet BMI and clinical criteria (BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or PAD). Members already on a Part D-covered GLP-1 are ineligible. The $50 copay does not count toward the $2,100 Part D cap or TrOOP.
Commercially insured SummaCare members whose plan covers Wegovy can use the NovoCare savings card to pay as little as $25/month (up to $100 savings per 28-day supply). The card is not available to Medicare Advantage or Medicaid beneficiaries under federal anti-kickback rules. If your SummaCare plan does not cover Wegovy, the NovoCare self-pay option (approximately $349/month) is available regardless of insurance status.
If your employer's SummaCare plan excludes weight-loss drugs, that is a benefit exclusion — not a medical-necessity denial — and appealing the PA decision will not change the outcome. Options include the NovoCare self-pay program (approximately $349/month), the Medicare GLP-1 Bridge for eligible Medicare Advantage members (from July 1, 2026), and compounded semaglutide through services like Curex if you prefer to skip insurance entirely. Ask your prescriber which path fits your clinical situation.
Related Articles
Does Wellcare Cover Eliquis? Coverage & Cost 2026
Yes — Wellcare covers Eliquis on 2026 Part D and Medicaid plans. IRA price: $231/30-day. See tier, $615 deductible, and $2,100 OOP cap.
Read moreDoes Humana Cover Forteo? 2026 Part D Guide | Curex
Humana often does not cover brand Forteo — generic teriparatide or Bonsity is preferred on Part D. PA required; $2,100 cap applies. Verify your plan.
Read moreDoes Highmark Cover Ozempic? 2026 Coverage Guide | Curex
Highmark covers Ozempic for T2D with standard prior auth — simpler than its strict Wegovy J-0184 anti-obesity policy. PA steps, tier, and 2026 cost facts.
Read moreDoes UnitedHealthcare Cover Cialis? 2026 | Curex
UnitedHealthcare does not cover Cialis for ED — Medicare bars it by law; OptumRx excludes it as a lifestyle drug. Generic tadalafil IS covered for BPH.
Read moreDoes BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreWhether or not SummaCare covers Wegovy, there's a path that skips insurance
You just saw how tangled Wegovy coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Wegovy. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with SummaCare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.